{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T02:11:52Z","timestamp":1792289512867,"version":"4.4.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Reports"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.pharep.2019.02.002","type":"journal-article","created":{"date-parts":[[2019,2,10]],"date-time":"2019-02-10T19:37:07Z","timestamp":1549827427000},"page":"393-398","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["The safety and efficacy of Guluronic acid (G2013) in ankylosing spondylitis: A randomized controlled parallel clinical trial"],"prefix":"10.1007","volume":"71","author":[{"given":"Sepideh","family":"Nazeri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad Reza","family":"Jamshidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8164-8831","authenticated-orcid":false,"given":"Mahdi","family":"Mahmoudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahdi","family":"Vojdanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7332-0510","authenticated-orcid":false,"given":"Shahin","family":"Khadem Azarian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanaz","family":"Afraei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2134-792X","authenticated-orcid":false,"given":"Shayan","family":"Mostafaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mostafa","family":"Hosseini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abbas","family":"Mirshafiey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"10.1016\/j.pharep.2019.02.002_bib0005","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2147\/TACG.S37325","article-title":"The genetic basis of ankylosing spondylitis: new insights into disease pathogenesis","volume":"7","author":"Tsui","year":"2014","journal-title":"Appl Clin Genet"},{"key":"10.1016\/j.pharep.2019.02.002_bib0010","doi-asserted-by":"crossref","first-page":"e4233","DOI":"10.1097\/MD.0000000000004233","article-title":"Risk factors of uveitis in ankylosing spondylitis: An observational study","volume":"95","author":"Sun","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.pharep.2019.02.002_bib0015","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.curtheres.2014.08.002","article-title":"Efficacy and safety of celecoxib in chinese patients with ankylosing spondylitis: a 6-week randomized, double-blinded study with 6-week open-label extension treatment","volume":"76","author":"Huang","year":"2014","journal-title":"Curr Ther Res Clin Exp"},{"key":"10.1016\/j.pharep.2019.02.002_bib0020","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.jaut.2014.01.015","article-title":"The classification and diagnostic criteria of ankylosing spondylitis","volume":"48","author":"Raychaudhuri","year":"2014","journal-title":"J Autoimmun"},{"key":"10.1016\/j.pharep.2019.02.002_bib0025","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1093\/rheumatology\/kev218","article-title":"Endoplasmic reticulum aminopeptidases in the pathogenesis of ankylosing spondylitis","volume":"54","author":"Kenna","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.pharep.2019.02.002_bib0030","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1186\/s12891-016-1275-5","article-title":"A randomized, clinical trial to assess the relative efficacy and tolerability of two doses of etoricoxib versus naproxen in patients with ankylosing spondylitis","volume":"17","author":"Balazcs","year":"2016","journal-title":"BMC Musculoskelet Disord"},{"key":"10.1016\/j.pharep.2019.02.002_bib0035","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1136\/annrheumdis-2015-207677","article-title":"Comparative efficacy of non-steroidal anti-inflammatory drugs in ankylosing spondylitis: a Bayesian network meta-analysis of clinical trials","volume":"75","author":"Wang","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.pharep.2019.02.002_bib0040","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1136\/ard.2006.054098","article-title":"No efficacy of subcutaneous methotrexate in active ankylosing spondylitis: a 16-week open-label trial","volume":"66","author":"Haibel","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.pharep.2019.02.002_bib0045","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.semarthrit.2006.08.003","article-title":"Ankylosing spondylitis: a contemporary perspective on diagnosis and treatment","volume":"36","author":"Mansour","year":"2007","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.pharep.2019.02.002_bib0050","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1136\/annrheumdis-2015-207897","article-title":"Effect of continuous versus on-demand treatment of ankylosing spondylitis with diclofenac over 2 years on radiographic progression of the spine: results from a randomised multicentre trial (ENRADAS)","volume":"75","author":"Sieper","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.pharep.2019.02.002_bib0055","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s13760-014-0392-x","article-title":"New therapeutic approach by G2013 in experimental model of multiple sclerosis","volume":"115","author":"Afraei","year":"2015","journal-title":"Acta Neurol Belg"},{"key":"10.1016\/j.pharep.2019.02.002_bib0060","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.intimp.2018.01.003","article-title":"Effects of guluronic acid (G2013) on SHIP1, SOCS1 induction and related molecules in TLR4 signaling pathway","volume":"55","author":"Mortazavi-Jahromi","year":"2018","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.pharep.2019.02.002_bib0065","first-page":"1","article-title":"G2013 modulates TLR4 signaling pathway in IRAK-1 and TARF-6 dependent and miR-146a independent manner","volume":"62","author":"Hajivalili","year":"2016","journal-title":"Cell Mol Biol (Noisy-le-Grand)"},{"key":"10.1016\/j.pharep.2019.02.002_bib0070","first-page":"216","article-title":"Efficacy and safety of G2013 as a novel immunosuppressive agent on differentiation, maturation and function of human dendritic cells","volume":"46","author":"Fard","year":"2017","journal-title":"Iran J Public Health"},{"key":"10.1016\/j.pharep.2019.02.002_bib0075","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/j.cct.2011.08.006","article-title":"Expansion of the modified Zelen\u2019s approach randomization and dynamic randomization with partial block supplies at the centers to unequal allocation","volume":"32","author":"Kuznetsova","year":"2011","journal-title":"Contemp Clin Trials"},{"key":"10.1016\/j.pharep.2019.02.002_bib0080","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1002\/art.21054","article-title":"Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial","volume":"52","author":"Wanders","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.pharep.2019.02.002_bib0085","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1007\/s10067-005-0132-y","article-title":"Nonsteroidal anti-inflammatory drug use in ankylosing spondylitis\u2014a population-based survey","volume":"25","author":"Zochling","year":"2006","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.pharep.2019.02.002_bib0090","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1002\/art.20985","article-title":"Evaluation of the efficacy of etoricoxib in ankylosing spondylitis: results of a fifty\u2010two\u2013week, randomized, controlled study","volume":"52","author":"van der Heijde","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.pharep.2019.02.002_bib0095","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/1529-0131(200101)44:1<180::AID-ANR24>3.0.CO;2-K","article-title":"Efficacy of celecoxib, a cyclooxygenase 2\u2013specific inhibitor, in the treatment of ankylosing spondylitis: a six\u2010week controlled study with comparison against placebo and against a conventional nonsteroidal antiinflammatory drug","volume":"44","author":"Dougados","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.pharep.2019.02.002_bib0100","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1080\/08923973.2017.1282512","article-title":"Preclinical and pharmacotoxicology evaluation of \u03b1-l-guluronic acid (G2013) as a non-steroidal anti-inflammatory drug with immunomodulatory property","volume":"39","author":"Nazeri","year":"2017","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"10.1016\/j.pharep.2019.02.002_bib0105","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1136\/annrheumdis-2011-201252","article-title":"Effect of non-steroidal anti-inflammatory drugs on radiographic spinal progression in patients with axial spondyloarthritis: results from the German Spondyloarthritis Inception Cohort","volume":"71","author":"Poddubnyy","year":"2012","journal-title":"Ann Rheum Dis"}],"container-title":["Pharmacological Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1734114018304821?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1734114018304821?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T20:37:54Z","timestamp":1752611874000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1016\/j.pharep.2019.02.002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["S1734114018304821"],"URL":"https:\/\/doi.org\/10.1016\/j.pharep.2019.02.002","relation":{},"ISSN":["1734-1140"],"issn-type":[{"value":"1734-1140","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The safety and efficacy of Guluronic acid (G2013) in ankylosing spondylitis: A randomized controlled parallel clinical trial","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharep.2019.02.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier B.V. on behalf of Institute of Pharmacology, Polish Academy of Sciences.","name":"copyright","label":"Copyright"}]}}